User profiles for P. Sever
 | Peter SeverProfessor of Clinical Pharmacology, Imperial College London Verified email at imperial.ac.uk Cited by 103457 |
[HTML][HTML] Interpretation of the evidence for the efficacy and safety of statin therapy
This Review is intended to help clinicians, patients, and the public make informed decisions
about statin therapy for the prevention of heart attacks and strokes. It explains how the …
about statin therapy for the prevention of heart attacks and strokes. It explains how the …
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants
Background Statins have been shown to reduce the risk of all-cause mortality among individuals
with clinical history of coronary heart disease. However, it remains uncertain whether …
with clinical history of coronary heart disease. However, it remains uncertain whether …
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials
Background The clinical benefit of LDL cholesterol lowering treatment in older patients remains
debated. We aimed to summarise the evidence of LDL cholesterol lowering therapies in …
debated. We aimed to summarise the evidence of LDL cholesterol lowering therapies in …
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
…, P Ruggenenti, R Schrier, P Sever, P Sleight… - Lancet, 2003 - thelancet.com
Background The benefits of reducing blood pressure on the risks of major cardiovascular
disease are well established, but uncertainty remains about the comparative effects of different …
disease are well established, but uncertainty remains about the comparative effects of different …
[HTML][HTML] Evolocumab and clinical outcomes in patients with cardiovascular disease
…, T Liu, SM Wasserman, PS Sever… - New England journal …, 2017 - Mass Medical Soc
Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by …
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by …
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo …
… =0·024), total cardiovascular events (389 vs 486, 0·79 [0·69–0·90], p=0·0005), and total
coronary events (178 vs 247, 0·71 [0·59–0·86], p=0·0005) were also significantly lowered. There …
coronary events (178 vs 247, 0·71 [0·59–0·86], p=0·0005) were also significantly lowered. There …
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as …
Background The apparent shortfall in prevention of coronary heart disease (CHD) noted in
early hypertension trials has been attributed to disadvantages of the diuretics and β blockers …
early hypertension trials has been attributed to disadvantages of the diuretics and β blockers …
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
Background The mechanisms by which hypertension causes vascular events are unclear.
Guidelines for diagnosis and treatment focus only on underlying mean blood pressure. We …
Guidelines for diagnosis and treatment focus only on underlying mean blood pressure. We …
[HTML][HTML] Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an …
…, T Saruta, J Schrader, R Schrier, P Sever, P Sleight… - The Lancet, 2021 - thelancet.com
Background The effects of pharmacological blood pressure lowering at normal or high-normal
blood pressure ranges in people with or without pre-existing cardiovascular disease …
blood pressure ranges in people with or without pre-existing cardiovascular disease …
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV
These guidelines update previous reports by working parties of the British Hypertension
Society (BHS) in 1989, 1 19932 and 1999. 3 Updating these guidelines is appropriate because, …
Society (BHS) in 1989, 1 19932 and 1999. 3 Updating these guidelines is appropriate because, …